secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001477932-24-003896
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx mid-year: Vet test in 15 countries, $23M milestones, human license target H2 2024
--------------------------------------------------------------------------------

- Nu.Q Vet Cancer Test now available in 15 countries via Antech, IDEXX, Fujifilm; aiming to triple 2023 test sales of 58,000.
- Received $23M in upfront and milestone payments from Heska (Antech) for veterinary test.
- Preparing data rooms for Nu.Q NETs, Nu.Q Lung, and Capture-PCR technologies; first human licensing deal targeted in H2 2024.
- Capture-PCR method for direct ctDNA detection submitted for peer review July 2024; early-stage cancer discrimination demonstrated.
- Active commercial discussions with major liquid biopsy, IVD, and oncology players.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793224003896/0001477932-24-003896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793224003896/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-003896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer